UBE3A Sequencing

Angelman syndrome is characterized by developmental delay/intellectual disability, speech impairment, ataxia, and unique behavior of inappropriate laughing, smiling, and excitability. Methylation-sensitive MLPA analysis is used to detect a deletion of the 15q11-q13 region and/or methylation defect. This testing identifies approximately 75% of individuals with Angelman syndrome (70% due to maternal deletion, 5% due to paternal UPD). Approximately 10-15% of cases are due to sequence variants in the UBE3A gene. This laboratory performs Sanger sequencing of the UBE3A gene.

Forms & Docs

Ordering

Place an order

Test Code
S0104

Turn Around Time
3-5 weeks

Billing

CPT Code
81406×1

Ordering Guidance

To be ordered if methylation and deletion analysis for Angelman syndrome was normal

If there are questions regarding this test, please contact Client Services at 617-553-5880 or clientservices@claritasgenomics.com

Details

Genes Covered
UBE3A

Methods
Sanger